Previous research has demonstrated that AML patients harboring DNMT3A mutations exhibit a reduction in naive CD8+ T cells and CD4+ effector memory T cells compared to controls without such mutations while concurrently showing an increase in CD4+ Tcm cells (39). Here, CD8A is linked to acute myeloid leukemia.